Review reveals treatment strategies for non-DLBCL PTLD and Hodgkin lymphoma in transplant patients, suggesting a need for tailored management approaches.
Monomorphic post-transplant lymphoproliferative disorders (PTLD) beyond diffuse large B-cell lymphoma (DLBCL) are rare, biologically heterogeneous entities with limited prospective data to guide treatment. DLBCL-PTLD, which comprises the majority of cases, is managed using approaches informed by prospective phase 2 studies, including reduction in immunosuppression (RIS) and a risk-adapted sequential chemoimmunotherapy (RSST) approach. In contrast, non-DLBCL subtypes such as Burkitt lymphoma, T and NK cell PTLD, and plasmacytic variants are less common and are typically treated using strategies extrapolated from established treatment algorithms used in immunocompetent patients and sporadic case reports. Classic Hodgkin lymphoma PTLD, although not classified as monomorphic, represents another distinct and clinically relevant subtype. This review summarizes the epidemiology, clinical features, treatment strategies, and outcomes associated with these less common PTLDs, aiming to provide a practical framework for their management.
No takes yet. Share an insight, caveat, or question.
Atallah‐Yunes et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: